Astera Labs director Stefan Dyckerhoff sells $4.7m in shares

Stefan A. Dyckerhoff, a director at Astera Labs, Inc. (NASDAQ:ALAB), sold common stock totaling approximately $4.7 million on October 7, 2026, according to a recent filing. The transactions also included an acquisition of shares through a restricted stock unit award.The insider sale comes as Astera Labs shares have surged 106% year-to-date, with the stock currently trading at $342.21, giving the company a market capitalization of $59.37 billion. According to InvestingPro analysis, the stock appears overvalued relative to its Fair Value and is featured on the platform’s Most Overvalued list. InvestingPro offers 19 additional exclusive tips for ALAB, including insights on the company’s volatility and valuation multiples.

Mr. Dyckerhoff disposed of a total of 12,499 shares of Astera Labs common stock at a price of $376.06 per share. These sales were executed pursuant to a Rule 10b5-1 trading plan, which was adopted by Mr. Dyckerhoff on December 1, 2025. The sales included 3,505 shares held directly, 8,333 shares held indirectly by a trust, and 661 shares held indirectly by a limited partnership. The total value of these sales amounted to $4,700,373.

On October 1, 2026, Mr. Dyckerhoff acquired 68 shares of Astera Labs common stock at a price of $311.57 per share, totaling $21,186. These shares represent an award of restricted stock units granted under the company’s 2024 Stock Option and Incentive Plan. The award was in lieu of cash compensation for quarterly non-employee director retainer fees and is subject to vesting based on continuous service.

Following these transactions, Mr. Dyckerhoff directly holds 47,019 shares of Astera Labs common stock. He also holds various indirect interests, including 286,400 shares through a trust, 2,648 shares through a limited partnership, and additional shares through several irrevocable trusts. Mr. Dyckerhoff disclaims beneficial ownership of these indirectly held shares except to the extent of his pecuniary interest.

In other recent news, Astera Labs reported second-quarter 2026 adjusted earnings that surpassed Wall Street expectations. The company achieved a record revenue of $392.4 million, marking a 104% increase from the previous year. Earnings per share came in at $0.80, exceeding the forecasted $0.69 by 15.9%. Needham raised its price target for Astera Labs to $425 from $260, maintaining a Buy rating, citing growth across all product lines. Northland provided an upgrade earlier, moving Astera Labs to Outperform due to positive earnings revisions and a favorable AI spending outlook. However, Northland had previously downgraded the stock to Market Perform, highlighting valuation concerns. The firm anticipates increased estimates as the Scorpio-X product line expands. These developments reflect a dynamic period for Astera Labs, with significant analyst attention and revised forecasts.